Navigation Links
Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
Date:1/28/2008

and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Contact:

Daron Evans

Chief Financial Officer

Nile Therapeutics, Inc.

510-281-7700

info@nilethera.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section of our Prospectus filed pursuant to Rule 424(b)(3) of the Securities Act of 1933, as amended, with the Securities and Exchange Commission on November 15,
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
2. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
3. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
4. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
5. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
6. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
7. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
8. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
9. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
10. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
11. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... -- GenVec, Inc. (NASDAQ: GNVC ) today announced the ... board of directors effective on October 24, 2014.   Dr. Horovitz ... its chairman from June 2006 to November 2013.  During his ... and Audit Committees of the board.  "We ... service to GenVec, and its stockholders," said Wayne T. ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Partners LLC, announced today that Ellen Teplitzky, an ... support for the pharmaceutical industry, has joined the ... of its legal services practice. NDA Partners ... expert witness and testimony, to top law firms ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
(Date:10/19/2014)... October 19, 2014 The Asian Automatic ... Asian with analysis and forecast of revenue. The Automatic ... to around $463.9 million by 2018, at a developing ... through the TOC of the Asian Automatic patient billing ... provided. This also provides a glimpse of the segmentation ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... Pharmos Corporation,(Nasdaq: PARS ) announced today that ... from the Company., Mr. Rubino joined Pharmos ... acquisition and the subsequent integration of Vela,Pharmaceuticals completed ... has been focused on key business development priorities ...
... Synthetech, Inc. (OTC,Bulletin Board: NZYM) has earned ... outstanding accomplishments in environmental, health,safety and security ... by,the Synthetic Organic Chemical Manufacturers Association (SOCMA) ... awards are highly,regarded and demonstrate Synthetech,s level ...
... Dec. 18 January 1, 2008 will mark the,ritualistic day ... The New,Year also brings added pressure to smokers as January ... For those resolving to make 2008 the start of a ... Laser Therapy,provided by Achieve Laser, is quickly becoming a very ...
Cached Biology Technology:Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company 2Synthetech Earns National Recognition for Performance Improvement Program 2Synthetech Earns National Recognition for Performance Improvement Program 3Laser Therapy Gives Smokers Hope for Successful New Year's Resolution 2
(Date:10/16/2014)... October 16, 2014 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... technologies including Wocket™, the Smart Wallet, at the 13 ... is a leading global conference on the intersection of ... Mark Anderson , founder and publisher of the ...
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... This release is also available in Chinese ... (September 28, 2010) -- The second law of thermodynamics is ... its implicit existential crunch. The tendency of a closed systems ... removed is a popular, if not depressing, "things fall apart" ...
... MT. ROYAL, NJ (September 28, 2010) "Migraine feels ... face," says author Andrew Levy in his interview on the ... of Our Heads". "It,s a metaphysical crisis." In the ... his personal experience with managing the pain of migraine, how ...
... (Sept. 28, 2010) -- A new book, RNA ... reviews our understanding of two RNA worlds: the primordial RNA ... and biocatalyst; and the contemporary RNA world, in which mRNA, ... operate. "[T]he plasticity of RNA stemming from ...
Cached Biology News:Tiny generators turn waste heat into power 2American Migraine Foundation launches new podcast series 2New book reviews ancient and modern worlds of RNA 2
... SYBR Safe DNA gel stain was developed ... than ethidium bromide for staining DNA in agarose ... only less mutagenic than ethidium bromide but SYBR ... of ethidium bromide. SYBR Safe stain comes as ...
... Service enables scientists who do not have access ... to have their biological samples tested for the ... easy as 1-2-3 Chose the analytes ... from the S&S antibody menu. Send your ...
... I nucleic acid gel stain is an ... bright fluorescence when bound to dsDNA and low ... dsDNA in gels using laser scanners or standard ... has also found uses in capillary electrophoresis, real-time ...
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic gel acid stain has also found ... bandshift assays. One mL stains 100 minigels. A ...
Biology Products: